Transgene S.a.

Institut Pasteur

Transgene S.a., Institut Pasteur

Transgene S.a. and Institute Pasteur

Jean-Pierre Lecocq

Marie-Paule Kieny

Luc Montagnier

Marc Girard

Michael J Courtney

Guy Rautmann

Simon Wain Hobson

Paul Tolstoshev

Richard Lathe

Gerard Loison

Robert Drillien

Richard Harvey

Jean-Marc Balloul

Yves Lemoine

Andre Capron

Jean-Marie Grzych

Sophie Jallat

Raymond Pierce

Luc-Henri Tessier

Paul Sondermeyer

The invention relates to an analog of human .alpha..sub.1 -antitrypsin characterized in that it is all or part of the protein corresponding to human .alpha..sub.1 -antitrypsin in which, in 358 position, the amino-acid is selected from among arginine and little or non-oxidizable natural amino-acids when they are integrated into a protein.

Derivatives of human .alpha..sub.1 -antitrypsin and process for their

The present invention relates to a vaccinia virus, characterised in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.

Vaccine against rabies and process for preparation thereof

The present invention relates to a vaccinia virus, characterized in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.

The present invention relates to vectors for cloning, in a host cell, hirudin or an analog of hirudin, characterized in that it comprises the gene for encoding hirudin or an analog of hirudin, and the elements for the expression of this gene in said host cell, said coding gene beginning, after the starting sequence, by an Ile codon and a Thr codon. This invention also relates to the process for the preparation of hirudin or analogs of hirudin as well as the hirudin or anologs of hirudin obtained.

Vectors, transformed cells and process for the preparation of hirudin

Functional block of DNA enabling to prepare hirudine from yeast, characterized in that it comprises at least:--the gene of hirudine or one of its variants (gene H); --A DNA sequence (S.sub.tr) comprising the signals providing for the transcription of the gene H by the yeast.

Vectors for the expression and secretion of hirudin by transformed yeasts

This invention relates to an immunogenic composition comprising a viral vector. The genome of the viral vector comprises a functional origin of replication of a poxvirus, a DNA fragment encoding a non-cleavable gp160, a DNA fragment encoding a signal peptide, and a promoter for expressing DNA fragments in mammalian cells.

Viral vector coding for a glycoprotein of the virus responsible for

Hirudin, pharmaceutical compositions comprising it and their use

A viral vector comprising at least a portion of the genome of the HIV virus, a gene encoding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.

Non-cleavable GP160 glycoproteins of HIV

The present invention relates to the development of a vaccine against schistosomiasis. It relates to a protein which includes the epitopes of the p28 protein, a poxvirus containing a gene coding for the said protein, a cell incorporating a vector for the expression of the said protein, a method for preparing the said protein, a DNA sequence coding for the p28 protein, a pharmaceutical composition, antibodies raised against the said protein and their application by way of diagnostic agents for schistosomiasis. The present invention also relates to the application of the said protein by way of an agent possessing glutathione S-transferase activity.

Protein recognized by antibodies raised against native P28 of

A viral vector comprising at least a portion of the genome of the HIV virus, a gene coding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.

Growing community of inventors

Reichsteet, France

Jean-Pierre Lecocq